Protagenic Therapeutics, Inc. (PTIX)

Protagenic Therapeutics Financials Overview

Financials in millions USD. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025
Operating Income Operating Income Growth	-4.26	-4.5	-2.59
Net Income Net Income Growth	5.46	1.37	-3.59
Earnings Per Share EPS Growth	2.94	0.59	-0.67
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025
Cash & Investments Cash & Investments Growth	0.57	1.51	0.01
Total Debt Total Debt Growth	-	-	2.45
Net Cash (Debt) Net Cash Growth	0.57	1.51	-2.43
Net Cash Growth	580.43%	-	-
Net Cash Per Share Net Cash Per Share Growth	0.30	0.65	-0.45

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025
Operating Cash Flow Operating Cash Flow Growth	-2	-2.81	-1.77
Capital Expenditures CapEx Growth	-0	-0	-
Free Cash Flow Free Cash Flow Growth	-2	-2.81	-1.77
Free Cash Flow Growth	-	-	-

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025
Period Ending	Sep 25, 2026	Mar 31, 2026	Mar 31, 2025
PE Ratio	0.28	0.90	-

Data Source: S&P Global Market Intelligence Last updated: Aug 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 25, 2026

Data Sources Report a data error